• Something wrong with this record ?

Estrogen Receptor Modulators in Viral Infections Such as SARS-CoV-2: Therapeutic Consequences

N. Abramenko, F. Vellieux, P. Tesařová, Z. Kejík, R. Kaplánek, L. Lacina, B. Dvořánková, D. Rösel, J. Brábek, A. Tesař, M. Jakubek, K. Smetana

. 2021 ; 22 (12) : . [pub] 20210618

Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc21025557

Grant support
CZ.02.1.01/0.0/0.0/16_019/0000785 Ministerstvo Školství, Mládeže a Tělovýchovy
PROGRES Q28 Univerzita Karlova v Praze

COVID-19 is a pandemic respiratory disease caused by the SARS-CoV-2 coronavirus. The worldwide epidemiologic data showed higher mortality in males compared to females, suggesting a hypothesis about the protective effect of estrogens against severe disease progression with the ultimate end being patient's death. This article summarizes the current knowledge regarding the potential effect of estrogens and other modulators of estrogen receptors on COVID-19. While estrogen receptor activation shows complex effects on the patient's organism, such as an influence on the cardiovascular/pulmonary/immune system which includes lower production of cytokines responsible for the cytokine storm, the receptor-independent effects directly inhibits viral replication. Furthermore, it inhibits the interaction of IL-6 with its receptor complex. Interestingly, in addition to natural hormones, phytestrogens and even synthetic molecules are able to interact with the estrogen receptor and exhibit some anti-COVID-19 activity. From this point of view, estrogen receptor modulators have the potential to be included in the anti-COVID-19 therapeutic arsenal.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025557
003      
CZ-PrNML
005      
20220119144600.0
007      
ta
008      
211013s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms22126551 $2 doi
035    __
$a (PubMed)34207220
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Abramenko, Nikita $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 120 00 Prague, Czech Republic
245    10
$a Estrogen Receptor Modulators in Viral Infections Such as SARS-CoV-2: Therapeutic Consequences / $c N. Abramenko, F. Vellieux, P. Tesařová, Z. Kejík, R. Kaplánek, L. Lacina, B. Dvořánková, D. Rösel, J. Brábek, A. Tesař, M. Jakubek, K. Smetana
520    9_
$a COVID-19 is a pandemic respiratory disease caused by the SARS-CoV-2 coronavirus. The worldwide epidemiologic data showed higher mortality in males compared to females, suggesting a hypothesis about the protective effect of estrogens against severe disease progression with the ultimate end being patient's death. This article summarizes the current knowledge regarding the potential effect of estrogens and other modulators of estrogen receptors on COVID-19. While estrogen receptor activation shows complex effects on the patient's organism, such as an influence on the cardiovascular/pulmonary/immune system which includes lower production of cytokines responsible for the cytokine storm, the receptor-independent effects directly inhibits viral replication. Furthermore, it inhibits the interaction of IL-6 with its receptor complex. Interestingly, in addition to natural hormones, phytestrogens and even synthetic molecules are able to interact with the estrogen receptor and exhibit some anti-COVID-19 activity. From this point of view, estrogen receptor modulators have the potential to be included in the anti-COVID-19 therapeutic arsenal.
650    _2
$a nádory prsu $x komplikace $x farmakoterapie $x patologie $7 D001943
650    _2
$a COVID-19 $x komplikace $x patologie $x virologie $7 D000086382
650    _2
$a modulátory estrogenních receptorů $x metabolismus $x farmakologie $x terapeutické užití $7 D020847
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a receptory pro estrogeny $x chemie $x metabolismus $7 D011960
650    _2
$a SARS-CoV-2 $x účinky léků $x izolace a purifikace $x fyziologie $7 D000086402
650    _2
$a proteiny virové matrix $x antagonisté a inhibitory $x metabolismus $7 D014763
650    _2
$a internalizace viru $x účinky léků $7 D053586
650    _2
$a replikace viru $x účinky léků $7 D014779
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Vellieux, Fréderic $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic
700    1_
$a Tesařová, Petra $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, 120 00 Prague, Czech Republic
700    1_
$a Kejík, Zdeněk $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 120 00 Prague, Czech Republic
700    1_
$a Kaplánek, Robert $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 120 00 Prague, Czech Republic
700    1_
$a Lacina, Lukáš $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Institute of Anatomy, First Faculty of Medicine, Charles University, 120 00 Prague, Czech Republic $u Department of Dermatovenereology, First Faculty of Medicine, Charles University and General University Hospital, 120 00 Prague, Czech Republic
700    1_
$a Dvořánková, Barbora $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Institute of Anatomy, First Faculty of Medicine, Charles University, 120 00 Prague, Czech Republic
700    1_
$a Rösel, Daniel $u BIOCEV, Faculty of Sciences, Charles University, 252 50 Vestec, Czech Republic
700    1_
$a Brábek, Jan, $u BIOCEV, Faculty of Sciences, Charles University, 252 50 Vestec, Czech Republic $d 1973- $7 xx0268678
700    1_
$a Tesař, Adam $u Department of Neurology, First Faculty of Medicine, Charles University, 120 00 Prague, Czech Republic
700    1_
$a Jakubek, Milan $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 120 00 Prague, Czech Republic
700    1_
$a Smetana, Karel $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Institute of Anatomy, First Faculty of Medicine, Charles University, 120 00 Prague, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 12 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34207220 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20220119144556 $b ABA008
999    __
$a ok $b bmc $g 1714558 $s 1146064
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 12 $e 20210618 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a CZ.02.1.01/0.0/0.0/16_019/0000785 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a PROGRES Q28 $p Univerzita Karlova v Praze
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options